biostudies-literatureAmarenco PFrench GovernmentSOS-ATTAQUE CEREBRALE ASSOCIATIONPfizerAstraZenecaMerck271-280https://www.ebi.ac.uk/biostudies/studies/S-EPMC6960693biostudies-literatureUnknown4(3)<h4>Background</h4>In patients with non-cardio-embolic stroke, atorvastatin 80 mg/day reduced the relative risk of recurrent stroke by 16%, and a post hoc analysis showed that achieving an LDL-c of less than 70 mg/dL reduced the relative risk by 28% as compared to an on-treatment LDL of 100 mg/dL or more. Current guidelines from the French drug agency recommend treating with a statin after an ischaemic stroke to a target of less than 100 mg/dL, but no study directly tested LDL-c targets. The Treat Stroke to Target (TST) trial will compare the efficacy of achieving an LDL-c of less than 70 mg/dL versus an achieved LDL-c of 100 ± 10 mg/dL for secondary prevention in patients with recent ischaemic stroke of atherosclerotic origin.Main hypothesis: An achieved on-treatment LDL-c of less than 70European stroke journalTreat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes.PMC6960693AOM0900 &amp; AOM10281Steg PGTouboul PJYelles NLabreuche JVicaut EGiroud MBruckert ESimon TKim JSNighoghossian NMahagne MHAmarenco PLee BCfalseTreat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes.<h4>Background</h4>In patients with non-cardio-embolic stroke, atorvastatin 80 mg/day reduced the relative risk of recurrent stroke by 16%, and a post hoc analysis showed that achieving an LDL-c of less than 70 mg/dL reduced the relative risk by 28% as compared to an on-treatment LDL of 100 mg/dL or more. Current guidelines from the French drug agency recommend treating with a statin after an ischaemic stroke to a target of less than 100 mg/dL, but no study directly tested LDL-c targets. The Treat Stroke to Target (TST) trial will compare the efficacy of achieving an LDL-c of less than 70 mg/dL versus an achieved LDL-c of 100 ± 10 mg/dL for secondary prevention in patients with recent ischaemic stroke of atherosclerotic origin.Main hypothesis: An achieved on-treatment LDL-c of less than 702019-01-01T00:00:00Z2019 Sep2025-04-26T06:15:35.144Z2020-05-22T08:32:35ZS-EPMC69606933198423510.1177/2396987319838100